1st Author Yr of publication Ref | -Were study subjects in sham controlled studies reported to be blind? (Yes / No / Unclear) -If yes / unclear, was the blinding tested for success? (Yes / No) -If yes, was it successful? (Yes / No) | -Were study subjects in studies with control group reported to be naive? (Yes / No / Unclear) -Was the origin of the subjects reported (Yes / No) -If yes, does it allow to exclude any interest? (Yes / No / Unclear) | Were study subjects reported to have been randomly allocated to study groups? (Yes / No / Unclear) | Were study groups comparable in relation to symptoms when studying symptomatic subjects (duration and pain intensity) (NA when cross-over study design)? (Yes / No) | Were the intervention and control(s) well described (at least where and how)? (Yes / No) | Was the assessor reported to be blind to group allocation? (Yes / No) | Were losses and exclusions of study subjects reported or obvious in result section (including in tables or graphs)? (Yes / No / Unclear) | Was the person who statistically analyzed the data reported to be blind to group allocation? (Yes / No) | Comments by the technical experts (i) on the statistical analysis, and (ii) in relation to the methodology and/or technical aspects |
---|---|---|---|---|---|---|---|---|---|
Quality score (risk of bias, also including an external validity criteria) and classification | |||||||||
Niazi 2015 [27] | -No -No -NA | None in relation to statistics No expert was available in relation to the technical aspects of this outcome measure | |||||||
2.5/6 (42%) medium | NA | = No 0 pt | Yes 1 pt | NA (SCP subjects) | -Yes 0.5 pt -No 0 pt | No 0 pt | Yes 1 pt | No 0 pt | |
Christiansen 2018 [28] | -No -Yes -Yes | None in relation to statistics No expert was available in relation to the technical aspects of this outcome measure | |||||||
5/6 (83%) acceptable | NA | = Unclear 0.5 pt | Yes 1 pt | NA (SCP subjects) | -Yes 0.5 pt -No 0 pt | Yes 1 pt | Yes 1 pt | Yes 1 pt |